Sartorius Stedim Biotech (DIM) Q2 2025 earnings summary

Executive summary

• H1 2025 saw group revenue grow 6% in constant currencies to €1.767 billion, driven by strong consumables demand and margin expansion; Bioprocess Solutions (BPS) outperformed, while Lab Products & Services (LPS) faced challenges from soft end markets.

• Underlying EBITDA rose 12% to €527 million, with margin nearing 30%; underlying EPS grew ~30% year-over-year.

• BPS sales grew nearly 9% year-over-year, while equipment sales remained soft; LPS sales declined 4% in constant currencies.

• Free cash flow increased to €122 million, supporting deleveraging; CapEx ratio at 9.1% for H1.

• Several new products launched to enhance customer efficiency and productivity; MatTek acquisition closed July 1, contributing positively to LPS.

Financial highlights

• Group sales up 6.1% in constant currencies to €1.767 billion; recurring business grew double-digit, non-recurring declined double-digit.

• Underlying EBITDA up 11.9% to €527 million; margin increased by 170 bps to 29.8%.

• Underlying EPS grew 13.5% to €2.44; reported net profit up 33% to €81 million.

• Operating cash flow at €289 million, down 16.6% year-over-year due to prior year working capital levers.

• Free cash flow up €14 million to €122 million; CapEx ratio at 9.1% for H1.

Outlook and guidance

• Full-year 2025 group revenue expected to grow 6% in constant currencies; BPS +7%, LPS +1%, all with ±2% range.

• EBITDA margin guidance: 29–30% for group, 31–32% for BPS, 22–23% for LPS.

• CapEx ratio projected at ~12.5%; net debt/EBITDA to decrease to ~3.5 by year-end.

• MatTek acquisition to add ~1% to LPS revenue in H2.

• Guidance excludes potential tariff impacts; management expects limited effect from new US/EU tariffs.